Brain-Computer Interface Market Heats Up, Founder Charges Investors 5,000 Yuan/Hour for Meetings
China's brain-computer interface (BCI) industry is experiencing a massive boom, attracting significant capital and leading to soaring company valuations, with some founders even charging investors for meetings.
Intelligence analysis by Gemini 2.5 Flash
The BCI sector in China is witnessing an unprecedented surge in investment, driven by favorable government policies and technological advancements. This intense interest has led to a rapid increase in the number of BCI companies and their valuations, though concerns about market overheating and speculative investments are also emerging.
Imagine if you could control a computer just by thinking, like a super-smart remote control for your brain! That's what brain-computer interfaces (BCI) are trying to do. Lots of grown-ups in China are super excited about this idea and are putting tons of money into companies trying to make it happen, hoping it can help people or even make us smarter. But some grown-ups are also worried that everyone is getting too excited too fast, and some companies might not be as good as they seem.
Analysis
The BCI Investment Frenzy
The brain-computer interface (BCI) industry in China is currently experiencing a fervent investment boom, with capital pouring into the sector at an unprecedented rate. Founders like Li Xiaojian of WeiLing Medical are so overwhelmed by investor interest that he charges 5,000 yuan per hour for meetings, noting that many institutions are merely 'learning' under the guise of investment. This enthusiasm extends across numerous BCI companies, including MingVision BCI, ZhiRan Medical, AoYi Technology, and RouLing Technology, all of whom have seen significant investor attention and rapidly escalating valuations.
This capital influx is not limited to traditional medical funds; industrial and technology funds are increasingly entering the BCI space. These new investors often view BCI, particularly invasive BCI, not just as a medical product but as a technology with immense potential across various future applications, contributing to the high valuations seen in the sector. The number of BCI-related enterprises in China has surged, with estimates now far exceeding previous reports, indicating a rapid expansion of the industry landscape.
Policy Tailwinds and Technological Leaps
The current BCI boom is significantly bolstered by strong policy support and tangible technological breakthroughs. The inclusion of BCI as one of six future industries in China's "15th Five-Year Plan" has provided a crucial policy tailwind. A landmark event was the approval of the world's first semi-invasive BCI by China's National Medical Products Administration in March, followed by its first human surgery in July, signaling a transition from scientific exploration to clinical application.
Beyond regulatory milestones, the industry has seen substantial technical advancements. Improvements in signal decoding accuracy, system integration capabilities, and multi-modal fusion in non-invasive deep brain control are noted. Experts like Huang Jinglu of Legend Capital observe that BCI has moved from a stage of uncertain potential to one of increasing certainty, with invasive BCIs now in clinical trials and product registration expected before 2028. This shift from theoretical possibility to practical implementation is a key driver of investor confidence.
Navigating Overheating and Future Challenges
Despite the excitement, there are growing concerns about market overheating and inflated valuations within the BCI sector. Some industry observers, including Li Xiaojian, liken the current investment climate to a "game of passing the buck," where capital chases high valuations for quick exits without fully understanding the underlying technology or long-term viability. There's a noted proliferation of "assembly companies" that lack proprietary core technology, relying instead on open-source solutions or mere conceptual presentations.
While Chinese companies are making strides, a gap still exists with international leaders like Neuralink, particularly in channel count for invasive BCIs. However, Chinese firms are innovating, such as ZhiRan Medical's development of stretchable, flexible electrodes inspired by traditional paper-cutting, designed to improve stability and reduce tissue damage. Experts predict that a "local high-valuation bubble" in BCI might burst in 2-3 years, citing unverified scientific mechanisms for many applications, the highly interdisciplinary nature of the field, and potential contractions in local government investment liquidity.
Key points
- China's BCI industry is experiencing a massive investment boom, with founders sometimes charging high fees for investor meetings.
- Policy support from the '15th Five-Year Plan' and regulatory approvals for semi-invasive BCIs are key drivers of this growth.
- Technological advancements are moving BCI from scientific exploration to clinical and industrial application, attracting diverse investment funds.
- Concerns exist about market overheating, inflated valuations, and the proliferation of companies lacking core proprietary technology.
- Chinese companies are innovating to close the gap with international leaders, particularly in areas like electrode design, despite challenges in chip technology.
China's robust policy support and significant capital investment could propel its BCI industry to global leadership, fostering breakthroughs that address critical medical needs and unlock new frontiers in human-computer interaction. Continued innovation, like stretchable electrodes, suggests a path to overcoming current technical limitations and achieving widespread adoption.
The current investment frenzy risks creating a speculative bubble, leading to inflated valuations for companies lacking genuine innovation or viable long-term products. A potential market correction could result in significant financial losses and a setback for legitimate BCI research if unproven scientific mechanisms fail to materialize into practical applications.
